WallStSmart
ACHL

Achilles Therapeutics PLC ADR

NASDAQ: ACHL · HEALTHCARE · BIOTECHNOLOGY

$1.48
+0.00% today

Updated 2026-06-05

Market cap
$63.22M
P/E ratio
P/S ratio
EPS (TTM)
$-1.66
Dividend yield
52W range
$0 – $0
Volume
1.2M

Achilles Therapeutics PLC ADR (ACHL) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item201820192020202120222023
Revenue$0.00$0.00$0.00$0.00$0.00
Revenue growth (YoY)
Cost of revenue$303250.00$778005.00$3.29M$3.69M$4.73M
Gross profit$-303250.00$-778005.00$-3.29M$-3.69M$-4.73M
Gross margin
R&D$4.80M$9.07M$22.63M$42.22M$57.26M$67.65M
SG&A$2.10M$4.70M$11.10M$21.97M$21.12M$17.01M
Operating income$-6.90M$-13.78M$-33.73M$-64.19M$-78.38M$-75.25M
Operating margin
EBITDA$-6.73M$-13.47M$-32.95M$-57.77M$-78.38M$-70.44M
EBITDA margin
EBIT$-6.90M$-13.78M$-33.73M$-61.05M$-82.07M$-75.17M
Interest expense$0.00$215000.00$531000.00$3.13M$7.32M
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-6.89M$-13.99M$-33.20M$-61.10M$-71.18M$-69.67M
Net income growth (YoY)-103.1%-137.3%-84.0%-16.5%+2.1%
Profit margin

Frequently asked questions

How much free cash flow does ACHL generate?

ACHL produced $-49.55M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is ACHL's balance sheet healthy?

ACHL holds $131.54M in cash and equivalents against — in long-term debt, on $142.37M of shareholder equity. That debt is best read against the cash flow the business throws off each year.